Drug Trial Radar · NCT01966653
Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women
Last checked: Nov 19, 2026Latest source record: May 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 2013
Primary completion
May 2017
Study completion Aug 2017
Sponsor
- Lead sponsor
- University Hospital, GenevaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Commission
- First posted
- Oct 21, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Developed before the establishment of a structured process for drug assessment, nitrofurantoin is now being prescribed frequently given the rise in multi-resistant gram-negative pathogens. Doubts remain regarding fosfomycin's long-term clinical effectiveness. A randomized, controlled trial is needed to explore the clinical effectiveness and better define the side effect profiles of both nitrofurantoin and fosfomycin. This multi-center open trial will randomize 600 non-pregnant women at three international sites (200 each in Poland, Switzerland, and Israel) at increased risk for carriage of resistant uropathogens and with suspicion of uncomplicated lower urinary tract infection to receive either oral nitrofurantoin 100 mg three times daily for 5 days or a single 3g dose of oral fosfomycin. Patients will be followed for clinical and bacteriologic response at days 14 and 28 post therapy completion. The study hypothesis holds that nitrofurantoin will be superior to fosfomycin in clinical efficacy at final follow-up.
Conditions
- Urinary Tract Infections
- Cystitis
Interventions
nitrofurantoinDrug
nitrofurantoin 100 mg po tid for 5 days
fosfomycinDrug
fosfomycin 3g po single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with clinical cure, clinical failure, or indeterminate clinical response (see description below)Time frame: at 28 days post therapy completion
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Tel Aviv University
Tel Aviv, Israel
Lodz University Hospital
Lodz, Poland
University Hospitals of Geneva
Geneva, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.